EIDD-1931 Treatment Tweaks CYP3A4 and CYP2C8 in Arthritic Rats to Expedite Drug Interaction: Implication in Oral Therapy of Molnupiravir

Mahir Bhardwaj; Dilpreet Kour; Garima Rai; Srija Bhattacharya; Diksha Manhas; Bhavna Vij; Ajay Kumar; Debaraj Mukherjee; Zabeer Ahmed; Sumit G Gandhi; Utpal Nandi

doi:10.1021/acsomega.3c09287

EIDD-1931 Treatment Tweaks CYP3A4 and CYP2C8 in Arthritic Rats to Expedite Drug Interaction: Implication in Oral Therapy of Molnupiravir

ACS Omega. 2024 Mar 15;9(12):13982-13993. doi: 10.1021/acsomega.3c09287. eCollection 2024 Mar 26.

Authors

Mahir Bhardwaj^{1

2}, Dilpreet Kour^{1

2}, Garima Rai³, Srija Bhattacharya⁴, Diksha Manhas^{1

2}, Bhavna Vij¹, Ajay Kumar^{1

2}, Debaraj Mukherjee^{2

4

5}, Zabeer Ahmed^{1

2}, Sumit G Gandhi^{2

3}, Utpal Nandi^{1

2}

Affiliations

¹ Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu 180001, India.
² Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.
³ Infectious Diseases Division, CSIR-Indian Institute of Integrative Medicine, Jammu 180001, India.
⁴ Natural Product and Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Jammu 180001, India.
⁵ Department of Chemical Sciences, Bose institute, Kolkata 700091, India.

Abstract

EIDD-1931 is the active form of molnupiravir, an orally effective drug approved by the United States Food and Drug Administration (USFDA) against COVID-19. Pharmacokinetic alteration can cause untoward drug interaction (drug-drug/disease-drug), but hardly any information is known about this recently approved drug. Therefore, we first investigated the impact of the arthritis state on the oral pharmacokinetics of EIDD-1931 using a widely accepted complete Freund's adjuvant (CFA)-induced rat model of rheumatoid arthritis (RA) after ascertaining the disease occurrence by paw swelling measurement and X-ray examination. Comparative oral pharmacokinetic assessment of EIDD-1931 (normal state vs arthritis state) showed that overall plasma exposure was augmented (1.7-fold) with reduced clearance (0.54-fold), suggesting its likelihood of dose adjustment in arthritis conditions. In order to elucidate the effect of EIDD-1931 treatment at a therapeutic regime (normal state vs arthritis state) on USFDA-recommended panel of cytochrome P450 (CYP) enzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) for drug interaction using the same disease model, we monitored protein and mRNA expressions (rat homologs) in liver tissue by western blotting (WB) and real time-polymerase chain reaction (RT-PCR), respectively. Results reveal that EIDD-1931 treatment could strongly influence CYP3A4 and CYP2C8 among experimental proteins/mRNAs. Although CYP2C8 regulation upon EIDD-1931 treatment resembles similar behavior under the arthritis state, results dictate a potentially reverse phenomenon for CYP3A4. Moreover, the lack of any CYP inhibitory effect by EIDD-1931 in human/rat liver microsomes (HLM/RLM) helps to ascertain EIDD-1931 treatment-mediated disease-drug interaction and the possibility of drug-drug interaction with disease-modifying antirheumatic drugs (DMARDs) upon coadministration. As elevated proinflammatory cytokine levels are prevalent in RA and nuclear factor-kappa B (NF-kB) and nuclear receptors control CYP expressions, further studies should focus on understanding the regulation of affected CYPs to subside unexpected drug interaction.